Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2− Breast Cancer Patient With High Tumor Mutational Burden

Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2− Breast Cancer Patient With High Tumor Mutational Burden

Endocrine treatment plus CDK4/6 inhibitors have become standard of care for estrogen receptor positive (ER+) breast cancer. Although immune checkpoint inhibitors (ICIs) have shown promising antitumor activity in a variety of cancer types, only limited success has been achieved for metastatic breast...

Full description

Bibliographic Details
Main Authors: Rong Wang, Yuchen Yang, Wei-Wu Ye, Jianxing Xiang, Songan Chen, Wei-Bin Zou, Xiao-Jia Wang, Tianhui Chen, Wen-Ming Cao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
breast cancer
immunotherapy
biomarker
TMB
NGS
molecular monitoring
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.588080/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.588080/full

Similar Items